Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET
**Dosage and Administration** **Dosage** **_Disorders of balance – Adults_** 25 mg tablet: 1 tablet three times a day. **_Prophylaxis of motion sickness:_** Adults and adolescents aged 13 years and above - 25 mg tablet: 1 tablet at least half an hour before travelling; to be repeated every 6 hours. Children aged 6 to 12 years: - Half of the adult dose is recommended. **Administration** STUGERON® should preferably be taken orally after meals.
ORAL
Medical Information
**Indications** - Disorders of balance – maintenance therapy for symptoms of labyrinthine disorders, including vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting. - Prophylaxis of motion sickness.
**Contraindications** STUGERON® is contraindicated in patients with known hypersensitivity to the drug.
N07CA02
cinnarizine
Manufacturer Information
JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE. LTD.
JANSSEN CILAG S P A
Active Ingredients
Documents
Package Inserts
Stugeron Tablet PI.pdf
Approved: March 31, 2023